FDA
-
-
-
-
-
-
-
9 Meters Biopharma (NMTR) Provides Business Update, Reports Q4
-
-
-
-
-
-
-
After-Hours Movers: Nautilus Gains on Strategic Review
-
-
-
-
-
-
-
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
-
-
-
-
-
-
-
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
-
-
-
-
-
-
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021
-
-
-
-
-
-
-
Pre-Open Stock Movers 04/07: (SOS) (NMTR) (UTME) Higher; (FGEN) (GEO) (FIXX) Lower (more...)
-
-
-
-
-
-
-
9 Meters Biopharma (NMTR) Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

